Health Updates

Low Intensity Extracorporeal Shockwave Therapy Safe and Effective in Mild-to-Moderate Erectile Dysfunction, Study Reveals

A recent study revealed that low-intensity extracorporeal shockwave therapy (Li-ESWT) is safe and effective in the treatment of vasculogenic erectile dysfunction (ED) in some patients.

Photo: Erectile Dysfunction | InStyleHealth

What is Erectile Dysfunction or ED ?

The term Erectile Dysfunction or ED is also known as “impotence”. Erectile Dysfunction is the inability to get or keep an erection firm enough to have sexual intercourse. A lot of men experience erectile dysfunction during times of stress. However, a frequent erectile dysfunction (ED) can be a sign of underlying health problems that need medical treatment. It can also be considered as a sign of emotional or relationship challenges that needed to be addressed by a professional.

The study involved 425 men with vasculogenic ED, who were assessed using the Sexual Health Inventory for Men (SHIM) scoring. All of the participants received the Li-ESWT using the Piezo Wave2 (Richard Wolf) device. Successful Li-ESWT was defined as having SHIM score of 22 – 25 at 6 months. Those with successful treatment were followed for 30 months.

The average SHIM score at nominal was 11.8, with a range of 5 – 20. Around half of the population (51.8%), patients reported satisfactory sexual intercourse at 6 months after they received the Li-ESWT treatment.

The following factors were included such as age, diabetes, hypertension, smoking, obesity, hyperlipidemia, pretreatment SHIM score, and the period of ED were all significantly correlated with the success of the Li-ESWT treatment.

For the 30-month follow-up with patients, 76.3% or 168 of them who responded to the Li-ESWT still reported satisfactory sexual intercourse with a SHIM score of 22 – 25 without requiring an oral phosphodiesterase type 5 or PDE5 inhibitor.

Results of the study showed that as much as 39.5% of the patients achieved the 30-month success with Li-ESWT. This option may be offered to patients with mild-to-moderate ED but not to those men with severe ED case. For complete details of this study, click here.


Source: Urology 2021;149:133-139

Previous Post Next Post
/*News Ticker*/